We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A triumvirate of aging-focused biotechs and researchers—the AI company Insilico Medicine, the portfolio-based startup Juvenescence and the nonprofit Buck Institute—have formed a new joint venture to develop small molecules for a novel target in a bid to e
GlaxoSmithKline has inked its second AI-based drug discovery deal of the summer. While the partners kept details under wraps, Insilico Medicine has its own drug discovery programs for age-related diseases, as well as cancer, diabetes and ALS.